46 results about "Volatile anesthetic" patented technology

The present invention provides therapeutic formulations, including therapeutic emulsions and nanoemulsions, and related methods for the delivery of fluorinated therapeutic compounds, including an important class of low boiling point perfluorinated and / or perhalogenated volatile anesthetics. Emulsion-based fluorinated volatile anesthetic formulations compatible with intravenous administration are provided that are capable of delivering and releasing amounts of fluorinated volatile anesthetic compounds effective for inducing and maintaining anesthesia in patients. Intravenous delivery of the present emulsion-based fluorinated volatile anesthetic formulations permits anesthetic levels in a patient to be selectively adjusted very rapidly and accurately without the need to hyperventilate patients and without the use of irritating agents.

The present invention provides methods for reducing pain in a subject in need thereof by delivering a volatile anesthetic in a solution or an emulsion that can additionally include an extractive solvent in an amount effective to reduce pain without substantially interfering with motor function. Chronic or acute pain may be treated, or the volatile anesthetic may be delivered as a regional anesthetic to a subject to anesthetize a portion of the subject prior to surgery. Dosing regimes including a one-time administration, continuous and / or periodic administration are contemplated.

Systems, methods, and apparatus for removing volatile anesthetics from an anesthesia or ventilation system to minimize the effects of malignant hyperthermia in susceptible patients. According to one aspect of the present invention, a system for removing volatile anesthetics is provided. A first filter component placed in fluid communication with an inspiratory limb of an anesthesia or ventilation system such that volatile anesthetics will pass through the first filter component during operation of the anesthesia or ventilation system. A second filter component is operably coupled to the expiration port of the anesthesia or ventilation system such that gases passing through the expiratory limb of the anesthesia or ventilation system pass through the second filter component. The first filter component and second filter component are adapted to effectively remove volatile anesthetics passing through the respective filters.

To provide a catalyst obtained by loading at least one noble metal selected from the group consisting of rhodium, ruthenium and palladium on a support selected from silica and silica alumina, and a method for decomposing nitrous oxide using the catalyst thereof. The catalyst for decomposing nitrous oxide of the present invention cannot be easily affected by a volatile anesthetic contained in a waste anesthetic gas, can recover the activity by activation and regeneration even when deteriorated, and can reduce the amount of NOx generated to less than the allowable concentration.

The present invention provides methods for treating inflammation or a wound in a subject in need of such wound treatment or inflammation treatment by delivering a volatile anesthetic to the wound or the inflammation site.

A therapy utilizing inhaled anesthetic agents (such as desflurane, sevoflurane, isoflurane, or xenon) for the sedation of patients outside of the immediate perioperative space such as in the medical intensive care unit (MICU) and the surgical intensive care unit (SICU). The therapy includes controlled delivery of volatile anesthetic agents to patients undergoing ventilatory support on an ICU ventilator over extended periods of time. A system which provides for the delivery of anesthetic agents includes an anesthetic agent vaporizer element, an anesthetic agent reflector, and a plug-in cassette which contains both a cartridge housing liquid phase volatile anesthetic agent and an anesthetic vapor scrubbing medium.

A therapy utilizing inhaled anesthetic agents (such as desflurane, sevoflurane, isoflurane, or xenon) for the sedation of patients outside of the immediate perioperative space such as in the medical intensive care unit (MICU) and the surgical intensive care unit (SICU). The therapy includes controlled delivery of volatile anesthetic agents to patients undergoing ventilatory support on an ICU ventilator over extended periods of time. A system which provides for the delivery of anesthetic agents includes an anesthetic agent vaporizer element, an anesthetic agent reflector, and a plug-in cassette which contains both a cartridge housing liquid phase volatile anesthetic agent and an anesthetic vapor scrubbing medium.

The invention discloses an anesthesia device for an animal experiment. The device is characterized by comprising an anesthesia case, a closed vessel filled with a volatile anesthetic; a seal door which can be opened is formed on the front side of the anesthesia case; communicating pipes which are communicated with the inside and the outside of the anesthesia case are arranged on two sides of the anesthesia case respectively; the communicating pipe on one side is arranged on the middle lower part of the case wall, and the communicating pipe on the other side is arranged on the upper part of the case wall; a sealing cover is arranged on the top of the closed vessel; and two straight pipes communicating the inside and the outside of the volatile anesthetic vessel are embedded on the sealing cover, one straight pipe is connected with the communicating pipe on the middle lower part of the case wall on one side of the anesthesia case through an anesthetic recycle device, and the other straight pipe is connected with the communicating pipe on the upper part on the case wall on the other side of the anesthesia case through a hose with a valve.

[Problem to be Solved]To provide a process and an apparatus for treating a waste anesthetic gas containing a volatile anesthetic and nitrous oxide, discharged from an operating room. [Means to Solve the Problem]A waste anesthetic gas containing a volatile anesthetic and nitrous oxide is introduced into an adsorbing cylinder filled with an adsorbent, where the volatile anesthetic contained in the waste anesthetic gas is adsorbed and thereby removed, and successively this gas is introduced into a catalyst layer filled with a nitrous oxide decomposition catalyst, where nitrous oxide is decomposed into nitrogen and oxygen.

The invention provides a catalyst obtained by loading at least one noble metal selected from the group consisting of rhodium, ruthenium and palladium on a support selected from silica and silica alumina, and a method for decomposing nitrous oxide using the catalyst thereof. The catalyst for decomposing nitrous oxide of the present invention cannot be easily affected by a volatile anesthetic contained in a waste anesthetic gas, can recover the activity by activation and regeneration even when deteriorated, and can reduce the amount of NOx generated to less than the allowable concentration.

The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic dissolved in a solution comprising an extractive solvent, e.g., DMSO or NMP, in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered as a regional anesthesia to a subject to anesthetize a portion the subject prior to a surgery, hi certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, or mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and / or periodic administration are contemplated.

The invention discloses a volatile anesthetic dosage monitoring system, belongs to the technical field of medical monitoring and solves the problems that in the prior art, the initially added anesthetic mass cannot be detected, the residual anesthetic mass cannot be detected in real time, the using speed of anesthetic cannot be detected, and the residual using time of residual anesthetic cannot be detected. The system comprises an anaesthesia machine which is provided with a display screen and a volatilization pot, wherein a weighing sensor is arranged between the anaesthesia machine and the volatilization pot. One end of the weighing sensor is electrically connected with a microprocessor which comprises an anesthetic initial mass operational module, an anesthetic residual mass operational module, an anesthetic residual volume operational module, a unit time anesthetic using speed operational module and a residual anesthetic using time operational module. The microprocessor is electrically connected with the display screen on the anesthesia machine. The invention further discloses a method for realizing the volatile anesthetic dosage monitoring system.

The invention provides a method for managing experimental animal respiration, which utilizes a clinic anesthesia machine for the anesthetization of the animal experiment, performs tracheal cannula on an animal, adopts an animal temperate maintenance instrument to keep warm, and keeps the body temperature at the physical level (37 plus or minus 0.5 DEG C) all the time during the anesthesia process. The method is used for solving the animal respiration management problem during the traditional anesthesia process, the same inhalation anesthesia concentration and the stable body environment are also maintained during the whole anesthesia process. By the method, not only is the stress response of the experimental animal reduced, but also the vital sign stability of the experimental animal can be maintained during the inhalation anesthesia process of a long time (such as 4 hours), the mortality is low and the reviving can be stable, and the influences of trauma stress, hypoxia-ischemia, hypercapnia, acidosis and other interference factors on the experimental result can be eliminated. The method effectively controls the respiratory tract of the experimental animal, and also maintains the inhalation anesthesia of the volatile anesthetics with constant concentration, which is output to the animal.

The present invention provides therapeutic formulations, including therapeutic emulsions and nanoemulsions, and related methods for the delivery of fluorinated therapeutic compounds, including an important class of low boiling point perfluorinated and / or perhalogenated volatile anesthetics. Emulsion-based fluorinated volatile anesthetic formulations compatible with intravenous administration are provided that are capable of delivering and releasing amounts of fluorinated volatile anesthetic compounds effective for inducing and maintaining anesthesia in patients. Intravenous delivery of the present emulsion-based fluorinated volatile anesthetic formulations permits anesthetic levels in a patient to be selectively adjusted very rapidly and accurately without the need to hyperventilate patients and without the use of irritating agents.

Methods for managing visceral pain in mammalian subjects are described, in which a NK-1 receptor antagonist is administered to the subject before, during or after administration of general anesthesia. The methods and uses of NK-1 receptor antagonists described herein provide improved visceral pain management and MAC reduction when used with volatile anesthetics for general anesthesia.

The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic such as a halogenated ether compound in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered to the subject to anesthetize the subject prior to a surgery. In certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, xenon, and mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and / or periodic administration are contemplated.

Systems, methods, and apparatus for removing volatile anesthetics from an anesthesia or ventilation system to minimize the effects of malignant hyperthermia in susceptible patients. According to one aspect of the present invention, a system for removing volatile anesthetics is provided. A first filter component placed in fluid communication with an inspiratory limb of an anesthesia or ventilation system such that volatile anesthetics will pass through the first filter component during operation of the anesthesia or ventilation system. A second filter component is operably coupled to the expiration port of the anesthesia or ventilation system such that gases passing through the expiratory limb of the anesthesia or ventilation system pass through the second filter component. The first filter component and second filter component are adapted to effectively remove volatile anesthetics passing through the respective filters.

The invention relates to a passive portable anesthesia machine. The passive portable anesthesia machine comprises a box, a breathing pipeline, an exhaling loop and an oxygen pipe, and is characterized in that an anesthetic gas concentration regulating and controlling device is arranged on the upper part inside the box; an anesthetic waste gas absorbing device is mounted at the bottom inside the box; the anesthetic waste gas absorbing device comprises an anesthetic storage tank, a waste gas absorbing particle storage tank A and a waste gas absorbing particle storage tank B; a waste gas pressure reducing valve A is connected with the bottom of the waste gas absorbing particle storage tank A; a primary anesthetic exhausting pipe and a secondary anesthetic exhausting pipe are connected with the bottom of the anesthetic gas concentration regulating and controlling device; one end of the exhaling loop extends out of the box, and the other end of the exhaling loop is communicated with the waste gas absorbing particle storage tank B; the oxygen pipe is communicated with the anesthetic gas concentration regulating and controlling device; the breathing pipeline is communicated with the secondary anesthetic exhausting pipe. The passive portable anesthesia machine has the advantages of being light in weight, wide in application range, free of an external power supply, capable of maintaining the concentration of a volatile anesthetic constant, and capable of maintaining the temperature of the anesthetic constant by heat generated during reaction of water and carbon dioxide in gas exhaled by a patient with the waste gas absorbing device.

The invention discloses a method for measuring concentration of volatile anesthetics in samples by automatic headspace gas chromatography. The method is suitable for measuring the concentrations of volatile anesthetics like methoxyflurane, enflurane, isoflurane, sevoflurane and desflurane in samples. The samples can be solutions containing the substances to be measured, as well as can be in vitro biological samples containing the substances to be measured, such as blood, urine, tissue fluid. The method is simple, fast and exact, suitable for measuring and analyzing laboratory samples, and suitable for result measurement of a plurality of samples in clinical monitoring.

An anaesthetic halocarbon capture system is provided. The system comprises a pressure-intolerant sleeve containing filter material for capturing one or more types of anaesthetic halocarbon prior to supercritical fluid extraction, and a pressure-tolerant housing into which the sleeve can be inserted so as to permit exposure of the sleeve contents to pressures required for supercritical fluid extraction.

An electric continuous flow device of a circulation circuit relates to a continuous flow device of a circulation loop, and solves the problems that a semi-open anesthetic loop for pediatric anesthesia causes low respiratory efficiency, the unutilized oxygen and volatile anesthetics are discharged into the atmosphere, medical resources are wasted, the environment is polluted, and a pediatric anesthetic close circulation loop has large resistance and high respiratory power consumption. A disc flow deflector is fixedly installed on a fan blade and is positioned at one side of an air inlet side, the external diameter of the disc flow deflector is d1, the external diameter of the fan blade is d2, and di equals to d2 minus 4mm; and the control signal output end of a touch screen is connected with the control signal input end of an external rotor electric machine, the signal output end of the external rotor electric machine is connected with the signal input end of the touch screen, the loop inspiration port of a respiration loop is communicated with the inspiration end of a disposable anesthetic loop through the external rotor electric machine, and the loop expiration port of the disposable anesthetic loop is communicated with a respiration loop through a dioxide carbon absorption unit. The electric continuous flow device is used in the anesthetic loop systems for children and adults.

Provided is a method of treating a patient having a tissue that is subject to an ischemic event. The method is conducted by parenterally administering a formulation containing a halogenated volatile anesthetic in an amount effective to improve the tissue's resistance to or tolerance of the ischemic event. In preferred embodiment of the invention, the amount of the formulation administered to the patient is sub-anesthetic. The formulation can be administered prior to, concurrently with, or after the ischemic event. The method can be used, for example, for treatment of patients having myocardial or neuronal tissue that is subject to an ischemic event.

Devices and methods of making and using the device for the non-invasive detection of volatile anesthetics are provided. The devices are capable of measuring the concentration of volatile anesthetics transdermally and in a non-invasive manner. The devices and methods can be applied in detection of volatile anesthetics in samples collected from human skin perspiration.

The present invention is concerned with the automated control of the synthesis and purification of components useful in the synthesis and purification of volatile anesthetics. The invention is particularly useful in its application to the purification of acetone used in the purification of isoflurane.

An electric continuous flow device of a circulation circuit relates to a continuous flow device of a circulation loop, and solves the problems that a semi-open anesthetic loop for pediatric anesthesia causes low respiratory efficiency, the unutilized oxygen and volatile anesthetics are discharged into the atmosphere, medical resources are wasted, the environment is polluted, and a pediatric anesthetic close circulation loop has large resistance and high respiratory power consumption. A disc flow deflector is fixedly installed on a fan blade and is positioned at one side of an air inlet side, the external diameter of the disc flow deflector is d1, the external diameter of the fan blade is d2, and di equals to d2 minus 4mm; and the control signal output end of a touch screen is connected with the control signal input end of an external rotor electric machine, the signal output end of the external rotor electric machine is connected with the signal input end of the touch screen, the loop inspiration port of a respiration loop is communicated with the inspiration end of a disposable anesthetic loop through the external rotor electric machine, and the loop expiration port of the disposable anesthetic loop is communicated with a respiration loop through a dioxide carbon absorption unit. The electric continuous flow device is used in the anesthetic loop systems for children and adults.

The invention belongs to the technical field of medical devices, and particularly relates to a medicine volatilization tank for an anaesthesia machine, the medicine volatilization tank comprises a volatilization cavity and absorbent cotton arranged in the volatilization cavity, the volatilization cavity is provided with an anesthetic inlet and two air vents, and anesthetic is injected into the absorbent cotton through the anesthetic inlet to be volatilized; the two air vents are respectively used as a gas inlet and an anesthetic mixed gas outlet, and gas introduced from one air vent is mixed with a volatile anesthetic and is discharged from the other air vent; the anesthetic is injected into the absorbent cotton for volatilization, so that waste of the anesthetic can be avoided, and stable anesthetic concentration can be guaranteed.

The invention discloses a preparation method of a fat emulsion composition for volatile anesthetic injection, which comprises the following steps: distributing emulsifiers into a first emulsifier and a second emulsifier according to a weight ratio of 1: 10-10: 1, and forming blank emulsion by the first emulsifier and oil for injection, the blank emulsion and the second part of emulsifier participate in forming a pre-emulsion, and the pre-emulsion and the volatile anesthetic participate in forming the fat emulsion composition for volatile anesthetic injection. In addition, the invention also provides an improved fat emulsion composition for volatile anesthetic injection, and the fat emulsion composition can not generate a bottle flushing phenomenon during high-temperature sterilization, and can be stored at room temperature for a long time.

Methods for managing visceral pain in mammalian subjects are described, in which a NK-1 receptor antagonist is administered to the subject before, during or after administration of general anesthesia. The methods and uses of NK-1 receptor antagonists described herein provide improved visceral pain management and MAC reduction when used with volatile anesthetics for general anesthesia.